Pular para o conteúdo principal
Ranking Invest

ASMB - Assembly Biosciences, Inc.

Segmento: HealthcareAssembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Análise Ranking Invest

Valuation estimado
-17,52%
$ 163.48 Mi
Valor de Mercado
$ 606.75 Mi
Sobrepreço (AV)+271.1%
IVR
0.27A companhia vale 0,27 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.24O valuation alternativo equivale a -24% do valor de mercado da companhia.
MLL
-0.24O lucro líquido dos controladores em 16 trimestres equivale a -24% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 305.65 Mi

Dívida Líquida

-$ 32.29 Mi

L4T

-$ 42.00 mil

MM4T

-43.15%

Indicadores Básicos

ROE

-0.01%

Índices de Previsibilidade

Receita Líquida

F0.47

Lucro

B0.17

Margem

D0.87

Índices de Tendência

Receita Líquida

A11.62

Lucro

A11.37

Margem

E-2.98

Índices de Endividamento

DIV/PAT

-0.11

DIV/L4T

768.71

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.